Renfu Pharmaceutical (600079.SH): HW241045 tablets approved for clinical trials of drugs

The Zhifong Finance and Economics APP reported that Renfu Medicine (600079.SH) announced that its wholly-owned subsidiary, Wuhan Renfu Innovative Drug Research Center Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" for HW241045 tablets issued by the National Medical Products Administration. HW241045 tablets are used for the treatment of idiopathic pulmonary fibrosis, and currently there are no drugs approved for marketing with the same target globally.